Monte Rosa Therapeutics, Inc. announced its second development candidate, MRT-6160, a novel, potent, and selective molecular glue degrader (MGD) of VAV1. The Company plans to file an Investigational New Drug (IND) application for MRT-6160 in the first half of 2024 and to develop the molecule as a potential treatment for autoimmune diseases.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.54 USD | -3.54% |
|
-11.94% | -37.35% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-37.35% | 224M | |
+34.01% | 52.85B | |
-8.02% | 38.87B | |
+34.86% | 38.24B | |
-11.12% | 26.79B | |
+12.56% | 26.16B | |
-19.62% | 19.9B | |
+39.18% | 13.18B | |
+31.47% | 12.24B | |
-3.40% | 11.79B |
- Stock Market
- Equities
- GLUE Stock
- News Monte Rosa Therapeutics, Inc.
- Monte Rosa Therapeutics Advances Second Development Candidate, MRT-6160, A Novel, Highly Selective Molecular Glue Degrader Targeting VAV1 for the Treatment of Autoimmune Diseases